Over 4,000 people are to receive compensation from Boehringer Ingelheim, the maker of Pradaxa as a part of an MDL settlement.
Pradaxa is a blood thinner that came in the U.S market in late 2010 heavily focused on its safety and efficacy as its selling point. However, in 2011, about 600 patients died after using Pradaxa and countless number of patients are experiencing the negative adverse effect of the drug.
The dangerous adverse effects of Pradaxa include:
- excessive bleeding
- gastrointestinal disorders
- heart attack
Pradaxa (marketed under the generic name, dabigatran) works by stopping the blood from clotting. It is used to prevent atrial fibrillation (irregular heartbeat), harmful blood clots, and stroke.
In May 2014, Boehringer Ingelheim, the company that made Pradaxa, publically announced that they would pay $650 million to settle all state and federal lawsuits filed by people who were affected by Pradaxa’s adverse effects. Mikal Watts, a member of the Plaintiff’s Committee stated, “We are proud of the settlement we have achieved, congratulations the company on doing the right thing, and we look forward to distributing these funds to our clients as expeditiously as possible.”
Boehringer Ingelheim is cited for misrepresenting the drug as a medication that doesn’t require prescription or doctor’s advice for dosage. The manufacturer is also accused of concealing the dangerous adverse effects of the drug and for failing to establish protocol about the drug’s usage.
For some Plaintiffs filing a lawsuit is their only alternative to recoup the money they spent for hospitalization and other necessary expenses brought by Pradaxa‘s adverse effects.